Syndax Pharmaceuticals, Inc. (SNDX)

Market Cap	776.58M
Revenue (ttm)	43.72M
Net Income (ttm)	-331.20M
Shares Out	86.05M
EPS (ttm)	-3.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,112,852
Open	9.34
Previous Close	9.30
Day's Range	9.02 - 9.40
52-Week Range	8.58 - 25.07
Beta	0.74
Analysts	Strong Buy
Price Target	35.91 (+297.9%)
Earnings Date	Jul 31, 2025

About SNDX

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combinati...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 3, 2016
• Employees: 270
• Stock Exchange: NASDAQ
• Ticker Symbol: SNDX
• Website: https://syndax.com

Analyst Forecast

According to 11 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is $35.91, which is an increase of 297.90% from the latest price.

Price Target

$35.91

(297.90% upside)

Analyst Consensus: Strong Buy